Insurance Coverage for Psychedelic-Assisted Therapy in Canada

The Canadian psychedelic-assisted therapy insurance landscape in 2026 is fragmented and substance-specific. There is no single "psychedelic therapy benefit" — coverage depends on which substance, which pathway (off-label vs Health-Canada-approved vs SAP (Health Canada's Special Access Program)), which insurer or government program, which province, and the patient's specific clinical situation. The most-likely-covered form is Spravato (intranasal esketamine) through private insurance prior authorization for documented TRD (treatment-resistant depression) — this is the only Health Canada-approved psychedelic-assisted-therapy product. Ketamine off-label has narrower private coverage (typically not on private formularies) but established workers' compensation pathways (WSIB (Ontario's Workplace Safety and Insurance Board) Ontario, WCB (Workers' Compensation Board) Alberta) and VAC (Veterans Affairs Canada) coverage for service-related TRD/chronic pain. Psilocybin and MDMA are SAP-only and largely uncovered — Quebec RAMQ (Régie de l'assurance maladie du Québec) has a psilocybin-specific public-funding precedent (Farzin/Stephan December 2022); VAC considers MDMA-AT case-by-case for service-related PTSD; psilocybin is not VAC-covered. Alberta Blue Cross became the first Canadian insurer to cover psychedelic-assisted therapy (March 2024) with a PAT (Psychedelic-Assisted Therapy) benefit, initially scoped to ketamine. This hub article aggregates the full Canadian coverage landscape into a navigable reference.

Quick-reference coverage matrix

Key takeaways

• Spravato is the most likely privately-covered psychedelic-assisted therapy product — Health Canada approved May 2020 for TRD; private prior-auth pathways (PSHCP Form M7520, Manulife, Sun Life, Green Shield, Blue Cross) widely available with documented TRD.
• Ketamine off-label has broader workers' compensation coverage (WSIB, WCB Alberta) and VAC coverage for service-related conditions; private insurance generally does not cover.
• Psilocybin and MDMA (both SAP-only) have very limited insurance pathways. Quebec RAMQ has a psilocybin-specific public-funding precedent. VAC covers MDMA case-by-case for PTSD but does NOT cover psilocybin.
• Alberta Blue Cross PAT (March 2024) — first Canadian insurer to cover psychedelic-assisted therapy. Initially scoped to ketamine with psilocybin/MDMA framed as future potential.
• Edmonton's Misericordia / Grey Nuns hospital ketamine program is the only Canadian publicly funded IV ketamine pathway (AHCIP-covered, ultra-resistant TRD).
• For most privately-insured Canadian patients with TRD: Spravato is typically the most affordable net-out-of-pocket pathway after prior authorization.
• For Canadian veterans with service-related conditions: ketamine has the most established VAC coverage; MDMA-AT case-by-case for PTSD; psilocybin not covered.

How to read this article

The Canadian insurance landscape is best understood by patient profile rather than by substance — your access pathway depends on what insurance/coverage you already have:

• Section 1: Private insurance with mental-health benefits — most Canadians employed by mid-to-large employers
• Section 2: Federal public servants (PSHCP / Canada Life) — particularly relevant to Ottawa's federal workforce
• Section 3: Alberta Blue Cross PAT — first Canadian psychedelic-assisted-therapy insurance
• Section 4: Veterans (Veterans Affairs Canada) — service-connected PTSD, TRD, chronic pain
• Section 5: Injured workers (workers' compensation) — WSIB Ontario, WCB Alberta, WorkSafeBC, CNESST Quebec, others
• Section 6: Provincial public drug plans — RAMQ Quebec, ODB Ontario, Pharmacare BC, others
• Section 7: AHCIP Edmonton public ketamine program — the only publicly funded IV ketamine pathway
• Section 8: Out-of-pocket — when no coverage applies

Substance-specific cost detail is in the following articles:

• Ketamine Therapy Cost in Canada
• Psilocybin-Assisted Therapy Cost in Canada
• MDMA-Assisted Therapy Cost in Canada

For the existing ketamine-specific insurance deep dive, see Insurance Coverage for Ketamine Therapy.

Section 1: Private insurance with mental-health benefits {#private}

If you have private extended-health benefits through your employer or individual policy, the practical pathway depends on the substance.

Spravato — the most likely-covered

Spravato (esketamine intranasal) is Health Canada-approved for TRD as of May 2020 and is the form most likely to be privately covered. Private prior-authorization pathways:

• Manulife, Sun Life, Green Shield, Blue Cross provincial branches — generally accept prior authorization for documented TRD with failed antidepressant trials. Specific forms vary by insurer.
• Documentation typically required: TRD diagnosis with documented failure of two or more adequate antidepressant trials in the current depressive episode; psychiatric/specialist consultation; treatment plan; Janssen Journey-certified provider.
• Reimbursement levels vary by plan — typically partial coverage with patient out-of-pocket after deductible and co-insurance. Many plans reimburse at 80% of lowest-priced equivalent.
• Net out-of-pocket for patients with private TRD coverage is often $0–$300 per session despite list price ~$800–$900.

For the Spravato deep dive, see Intranasal Ketamine and Spravato.

Off-label ketamine — generally not covered

Off-label generic ketamine (IV, IM, sublingual) for psychiatric use is generally not covered by private extended-health plans because off-label-no-Canadian-indication does not align with standard formulary inclusion criteria. Therapy fees (preparation/integration psychotherapy) may be partially covered as standard psychotherapy when delivered by a registered profession (Registered Psychotherapist, Registered Psychologist, Registered Clinical Counsellor, Registered Social Worker depending on province).

For the ketamine cost framework, see Ketamine Therapy Cost in Canada.

Psilocybin and MDMA — drug not covered

For both SAP-only substances, the drug itself is essentially never covered by private insurance (Schedule III/I, no approved Canadian indication). Therapy fees (preparation/integration psychotherapy) may be partially covered as standard psychotherapy.

Section 2: Federal public servants (PSHCP / Canada Life) {#pshcp}

The Public Service Health Care Plan (PSHCP), administered by Canada Life, covers approximately 1.5 million federal public servants, retirees, and dependants. PSHCP is particularly relevant for Ottawa's federal workforce but applies to federal public servants nationwide.

Spravato coverage: PSHCP has a documented prior-authorization pathway via Form M7520 (Canada Life's Spravato request form). Eligibility typically requires:

• Documented TRD with failed antidepressant trials
• Spravato + concurrent oral SSRI/SNRI
• Janssen Journey-certified clinical setting
• Psychiatric/specialist prescription

Reimbursement: at 80% of lowest-priced generic equivalent as of January 2024.

Practical implications: PSHCP's Spravato pathway is one of the most established and accessible private insurance routes to psychedelic-assisted therapy in Canada. For federal public servants in Ottawa specifically, this pathway connects to clinical providers including the Royal Ottawa BMO Innovative Clinic for Depression and FlowState Therapy.

For the PSHCP deep dive, see PSHCP / Canada Life Spravato Coverage (Form M7520).

For Ottawa-specific clinical context, see Ketamine Therapy in Ottawa.

Section 3: Alberta Blue Cross PAT (March 2024) {#alberta-blue-cross}

Alberta Blue Cross became the first Canadian insurer to cover psychedelic-assisted therapy with their PAT (Psychedelic-Assisted Therapy) coverage launched March 2024. ATMA CENA was a partner in the announcement.

Coverage scope at launch:

• Ketamine-assisted therapy is the covered form. KAT programs eligible under drug + psychology benefits within group, workplace, and individual plans.
• Psilocybin and MDMA: framed as future potential once formally legalized for therapy in Canada (i.e., once Health Canada approval is obtained). Confirm current scope with Alberta Blue Cross.

Practical implications:

• For Albertan patients with Alberta Blue Cross PAT-eligible plans, this is the first formal Canadian private insurance pathway for ketamine-assisted therapy
• ATMA CENA's KAT services are designed to be eligible under this coverage (subject to specific plan and prior-authorization requirements)

For the Alberta Blue Cross deep dive, see Alberta Blue Cross PAT Coverage.

Section 4: Veterans Affairs Canada {#vac}

Veterans Affairs Canada covers psychiatric and pain treatments for service-connected conditions. Coverage varies substantially by substance:

Ketamine — established VAC coverage

VAC covers ketamine drug forms (IV, oral, intranasal, compounded cream) for service-related TRD and chronic pain on a case-by-case basis. Per the December 2024 VAC mental-health treatments briefing, approximately 433 veterans averaged ~$10,109 in FY2024–25 ketamine coverage. The coverage infrastructure is established; specific case approval still required.

MDMA-AT — case-by-case for PTSD

VAC considers MDMA-AT case-by-case for service-related PTSD where SAP-approved. Less established than ketamine coverage volume, but a real pathway for veterans pursuing the SAP-pathway MDMA-AT. The Mithoefer 2018 Lancet Psychiatry Phase 2 evidence specifically in service-connected populations strengthens these applications.

Psilocybin — does NOT cover

VAC does NOT currently cover psilocybin-assisted therapy, citing insufficient evidence in veteran-specific populations. This is a meaningful contrast to ketamine and MDMA coverage.

Service-related qualification

For all three substances, VAC coverage requires service-related diagnosis — PTSD, TRD, or chronic pain connected to service in the Canadian Armed Forces, RCMP, or other eligible service. The ATMA CENA intake screens for VAC eligibility during the information call.

For the VAC deep dive, see VAC Coverage for Psychedelic-Assisted Therapy.

For substance-specific veterans content: Ketamine Therapy for PTSD, MDMA-Assisted Therapy for Veterans.

Section 5: Workers' compensation {#workers-comp}

Canadian workers' compensation boards have varied coverage frameworks for psychedelic-assisted therapy. The strongest formal pathway is for ketamine.

WSIB Ontario — multiple specialty formularies

WSIB Ontario lists ketamine and esketamine on multiple specialty formularies with prior authorization for compensable injuries:

• Psychotraumatic (22WS) — for compensable PTSD
• Serious Injury (27WS) — for serious-injury claims
• Musculoskeletal — for compensable musculoskeletal pain
• CNS/PNS — for nervous system injury pain
• Chronic Pain Disability — for chronic pain claims

Ontario presumptive PTSD legislation (Bill 163, expanded October 2024) provides accelerated eligibility for designated first responders — firefighters, police, paramedics, nurses, 911 dispatchers, corrections officers, wildland firefighters, wildland fire investigators. The presumption accelerates the underlying PTSD diagnosis but does not auto-approve specific treatments; case-by-case ketamine prior authorization still applies.

Psilocybin and MDMA: not formally listed on WSIB Ontario formularies at this time. Possible case-by-case review for compensable PTSD.

WCB Alberta

WCB Alberta has a documented Pharmaceutical Ketamine and Esketamine procedure covering compensable CRPS and refractory neuropathic pain. Bill 27 establishes presumptive PTSD coverage for first responders.

Psilocybin and MDMA: not formally listed.

WorkSafeBC

WorkSafeBC reviews ketamine and other psychedelic-assisted therapy claims case-by-case. WorkSafeBC's Evidence-Based Practice Group has published reviews on IV and oral ketamine for chronic non-cancer pain (2025 update); the position is cautious. No formal psilocybin or MDMA listings.

CNESST Quebec, WCB Manitoba, WCB Saskatchewan, WCB Nova Scotia

Case-by-case reviews; no formal listings comparable to WSIB Ontario or WCB Alberta.

For the workers' compensation deep dive, see Workers' Compensation for Psychedelic-Assisted Therapy.

Section 6: Provincial public drug plans {#provincial}

Provincial public drug plans (Pharmacare programs) generally do not cover psychedelic-assisted therapy. Specific decisions:

• Ontario Drug Benefit (ODB) — Spravato not on standard formulary. EAP (Exceptional Access Program) requests via SADIE portal — case-by-case.
• BC PharmaCare — non-benefit decision on Spravato. Generic ketamine for psychiatric use not on formulary.
• Quebec RAMQ — INESSS recommended against listing Spravato November 2020. Generic ketamine for psychiatric use not on formulary. Exception: psilocybin-assisted therapy via the Farzin/Stephan December 2022 precedent — first publicly funded psychedelic therapy in Canada. RAMQ subsequently modified billing codes for further claims for SAP-approved Quebec patients. See Psilocybin Therapy in Quebec.
• Alberta Health / AHCIP — provincial formulary coverage is limited. Edmonton Misericordia/Grey Nuns IV ketamine program is the AHCIP-covered exception (Section 7 below).
• Saskatchewan Drug Plan, Manitoba Pharmacare, Nova Scotia Pharmacare, others — generally non-benefit.

The Quebec RAMQ psilocybin precedent is the only established Canadian provincial public-funding pathway for any psychedelic therapy. It is real, capacity-limited, and dependent on physician engagement.

Section 7: AHCIP Edmonton Misericordia / Grey Nuns IV ketamine program {#edmonton}

The Misericordia and Grey Nuns Hospital ketamine program in Edmonton — operated by Covenant Health — is the only Canadian publicly funded outpatient psychiatric IV ketamine program. Coverage: AHCIP (Alberta Health Care Insurance Plan) for eligible Alberta residents. The program is available to all Albertans meeting the eligibility criteria.

Eligibility: ultra-resistant TRD with psychiatric referral; documented exhaustion of conventional treatments.

Practical implications: for Alberta residents with severe TRD, this is the only publicly funded Canadian IV ketamine pathway. Capacity is limited; psychiatric referral required.

For the Edmonton context, see Ketamine Therapy in Edmonton and Ketamine Therapy for Treatment-Resistant Depression (deep dive).

Section 8: Out-of-pocket — when no coverage applies {#out-of-pocket}

When no insurance pathway applies, patients face out-of-pocket costs across the substance options:

• Ketamine at ATMA CENA's KAT (ketamine-assisted therapy) pricing tiers: CAD $1,530–$6,930 per program (Psycholytic, Psychedelic, or Customized pathway). Drug bundled in clinical fees.
• Spravato without coverage: ~$800–$900 per session. Full induction (~12 sessions over 8 weeks): ~$9,600–$10,800.
• Psilocybin (SAP): ~CAD $2,500–$6,500 per program. Filament Health often supplies SAP-approved psilocybin at no charge — meaningful Canadian-specific cost reduction.
• MDMA-AT (SAP): ~CAD $7,500–$15,000 per program — highest of the three substances.

For substance-specific cost detail:

• Ketamine Therapy Cost in Canada
• Psilocybin-Assisted Therapy Cost in Canada
• MDMA-Assisted Therapy Cost in Canada

How to find your coverage pathway

A practical decision tree:

1. Are you a federal public servant or PSHCP-eligible? → PSHCP / Canada Life Spravato pathway is your most accessible private prior-auth route. See Section 2.
2. Are you a Canadian veteran with service-connected condition? → VAC pathway. Ketamine is most established; MDMA-AT case-by-case for PTSD; psilocybin not covered. See Section 4.
3. Are you an injured worker with compensable PTSD or chronic pain? → Workers' compensation. WSIB Ontario most established; WCB Alberta strong; others case-by-case. See Section 5.
4. Are you a Quebec resident with end-of-life distress? → RAMQ psilocybin Farzin/Stephan precedent may apply. See Section 6.
5. Are you an Alberta resident with Alberta Blue Cross PAT eligibility? → Alberta Blue Cross PAT. See Section 3.
6. Are you an Alberta resident with ultra-resistant TRD? → AHCIP Edmonton Misericordia/Grey Nuns may apply. See Section 7.
7. Do you have private extended-health with mental-health benefits? → Spravato prior-auth pathway most likely. See Section 1.
8. None of the above? → Out-of-pocket; see Section 8.

Frequently asked questions

What's the most accessible private insurance pathway for psychedelic-assisted therapy in Canada? Spravato (intranasal esketamine) for documented TRD via private prior authorization — particularly through PSHCP/Canada Life Form M7520 for federal public servants, and through Manulife, Sun Life, Green Shield, and Blue Cross provincial branches for other privately-insured patients.

Why is Spravato more covered than off-label ketamine? Spravato is Health Canada-approved (May 2020 for TRD); private insurance prior-auth pathways align with approved indications. Off-label generic ketamine has no Canadian approved psychiatric indication, so it doesn't fit standard formulary inclusion criteria.

Does VAC cover psychedelic-assisted therapy for veterans? Yes for ketamine (drug forms for service-related TRD/chronic pain — established pathway, ~433 veterans in FY2024-25). Yes case-by-case for MDMA-AT for service-related PTSD. No for psilocybin — VAC does not currently cover psilocybin-assisted therapy.

Does Quebec RAMQ cover any psychedelic therapy? Yes for psilocybin-assisted therapy via the December 2022 Farzin/Stephan precedent for SAP-approved Quebec patients with end-of-life distress. Not for ketamine, Spravato, or MDMA — RAMQ has not extended public funding to other psychedelic therapies.

Does Alberta Blue Cross PAT cover psilocybin and MDMA? At the March 2024 launch, the covered scope was ketamine-assisted therapy. Psilocybin and MDMA were framed as future potential once formally legalized for clinical use in Canada. Verify the current scope directly with Alberta Blue Cross, as coverage may have evolved.

What about WSIB Ontario for first responders with PTSD? WSIB covers ketamine and esketamine on multiple specialty formularies including Psychotraumatic and Serious Injury. Bill 163 presumptive PTSD legislation accelerates eligibility for designated first responders. Psilocybin and MDMA are not formally listed; case-by-case review may apply.

Is there any Canadian publicly funded psychedelic therapy? Yes — Edmonton Misericordia/Grey Nuns IV ketamine program (AHCIP-covered for ultra-resistant TRD); Quebec RAMQ for psilocybin SAP patients with end-of-life distress (Farzin/Stephan precedent). These are the only established public-funding pathways.

What's the most cost-efficient pathway for most Canadian patients? Depends on profile. For privately-insured patients with TRD: Spravato with prior auth often nets $0–$300 per session despite list price ~$800. For service-connected veterans: VAC ketamine pathway. For injured workers: WSIB/WCB pathway. For uninsured patients: SAP-pathway psilocybin (with Filament's no-charge drug supply) at ~$2,500–$6,500 per program is often cheapest.

Can I appeal a denied insurance application? Yes. Most insurers and government programs have appeal processes. Specific pathways vary. Documentation of additional clinical justification, alternative treatment failures, or specialist consultation is typically required for appeals. Discuss with your prescribing physician.

Where can I get help navigating coverage?

Sources

1. Health Canada DPD — Spravato: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
2. Canada Life — Spravato Prior Authorization Form M7520 (PSHCP): https://www.welcome.canadalife.com/content/dam/canadalife/documents/forms/you-and-your-family/1-0-employer/1-3-request-an-assessment/1-3-2-prior-auth-drugs/en/pshcp/spravato-m7520.pdf
3. PSHCP Member Site — Canada Life: https://www.welcome.canadalife.com/pshcp
4. Alberta Blue Cross — psychedelic-assisted therapy coverage announcement (March 2024): https://www.atmajourney.com/alberta-blue-cross-covers-pat/
5. Veterans Affairs Canada — Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
6. WSIB Ontario — Ketamine and Esketamine Formulary Decision: https://www.wsib.ca/en/drug-formulary-listing-decision-ketamine-and-esketamine
7. WSIB Ontario — PTSD First Responders Policy: https://www.wsib.ca/en/operational-policy-manual/posttraumatic-stress-disorder-first-responders-and-other-designated
8. WCB Alberta — Pharmaceutical Ketamine and Esketamine: https://www.wcb.ab.ca/about-wcb/procedures-manual/pharmaceutical-ketamine-and-esketamine.html
9. WorkSafeBC — Evidence-Based Practice Group: IV/Oral Ketamine: https://www.worksafebc.com/en/resources/health-care-providers/guides/issues-on-iv-ketamine-and-oral-ketamine-for-chronic-non-cancer-pain-2025-update
10. CDA-AMC — Spravato CDEC Final Recommendation (December 2020): https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0621%20Spravato%20-%20CDEC%20Final%20Recommendation%20December%2018,%202020_for%20posting.pdf
11. INESSS — Spravato Quebec recommendation (November 2020): https://www.inesss.qc.ca/en/themes/medicaments/drug-products-undergoing-evaluation-and-evaluated/extract-notice-to-the-minister/spravato-5429.html
12. Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
13. TheraPsil — Quebec first province to cover psilocybin therapy: https://therapsil.ca/quebec-first-province-to-cover-costs-of-psilocybin-assisted-psychotherapy-done-by-two-physicians/
14. Filament Health: https://filament.health/
15. Covenant Health — Edmonton Misericordia/Grey Nuns IV ketamine program: https://covenanthealth.ca/news-and-events/news/ketamine-used-to-treat-depression-at-the-misericordia-and-grey-nuns-hospitals
16. PsyCan / Psychedelics Canada: https://psychedelicscanada.org/
17. MAPS Canada: https://www.mapscanada.org/

Related articles

• PSHCP / Canada Life Spravato Coverage (Form M7520)
• Alberta Blue Cross PAT Coverage
• VAC Coverage for Psychedelic-Assisted Therapy
• Workers' Compensation for Psychedelic-Assisted Therapy
• Insurance Coverage for Ketamine Therapy
• Ketamine Therapy Cost in Canada
• Psilocybin-Assisted Therapy Cost in Canada
• MDMA-Assisted Therapy Cost in Canada
• Psilocybin Therapy in Quebec
• Ketamine Therapy in Edmonton
• MDMA-Assisted Therapy for Veterans

Last updated: 2026-05-06